Appealing targets for immunomodulation by VHHkappa conjugates include OX40, CD25, GITR, CD47 and CD73.7,8,48 Our findings support the pursuit of bispecific antibody engagers to target additional cancer-specific and immunomodulatory markers. Here, TNFRSF18 is linked to cancer.